248 related articles for article (PubMed ID: 23573240)
21. The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
Jamali-Raeufy N; Mojarrab Z; Baluchnejadmojarad T; Roghani M; Fahanik-Babaei J; Goudarzi M
Metab Brain Dis; 2020 Mar; 35(3):539-548. PubMed ID: 32016817
[TBL] [Abstract][Full Text] [Related]
22. Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats.
Bülbül M; Sinen O; Özkan A; Aslan MA; Ağar A
Exp Neurol; 2019 Jul; 317():78-86. PubMed ID: 30825442
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
Zhang FL; He Y; Zheng Y; Zhang WJ; Wang Q; Jia YJ; Song HL; An HT; Zhang HB; Qian YJ; Tong YL; Dong L; Wang XM
CNS Neurosci Ther; 2014 Dec; 20(12):1036-44. PubMed ID: 25399812
[TBL] [Abstract][Full Text] [Related]
24. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats.
Yin WL; Yin WG; Huang BS; Wu LX
Neurosci Lett; 2017 Sep; 657():45-52. PubMed ID: 28764908
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of Nrf2-ARE activator on dopaminergic neuronal loss in Parkinson disease model mice: Possible involvement of heme oxygenase-1.
Inose Y; Izumi Y; Takada-Takatori Y; Akaike A; Koyama Y; Kaneko S; Kume T
Neurosci Lett; 2020 Sep; 736():135268. PubMed ID: 32712353
[TBL] [Abstract][Full Text] [Related]
27. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Mandel RJ
Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
[TBL] [Abstract][Full Text] [Related]
28. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
[TBL] [Abstract][Full Text] [Related]
29. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
30. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
31. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Datla KP; Blunt SB; Dexter DT
Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
[TBL] [Abstract][Full Text] [Related]
32. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Jeon MY; Lee WY; Kang HY; Chung EJ
Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
[TBL] [Abstract][Full Text] [Related]
33. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
[TBL] [Abstract][Full Text] [Related]
34. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
[TBL] [Abstract][Full Text] [Related]
35. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
37. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism.
Adu TS; Mabandla MV
Metab Brain Dis; 2019 Dec; 34(6):1557-1564. PubMed ID: 31332728
[TBL] [Abstract][Full Text] [Related]
38. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
[TBL] [Abstract][Full Text] [Related]
39. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
40. Salidroside Protection Against Oxidative Stress Injury Through the Wnt/β-Catenin Signaling Pathway in Rats with Parkinson's Disease.
Wu DM; Han XR; Wen X; Wang S; Fan SH; Zhuang J; Wang YJ; Zhang ZF; Li MQ; Hu B; Shan Q; Sun CH; Lu J; Zheng YL
Cell Physiol Biochem; 2018; 46(5):1793-1806. PubMed ID: 29705802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
